Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen
study id #: NCT04674618
condition: Muscular Atrophy, Spinal, Ultrasound
Intrathecal administration of Nusinersen, an antisense oligonucleotide capable of increasing Survival Motor Neuron protein production, has been tested in Spinal Muscular Atrophy (SMA) to improve motor function and survival. A feature of adult SMA patients is a progressive neuromyopathic scoliosis, so spinal nusinersen administration can be challenging. Landmark identification using a pre-procedure ultrasound (US) facilitates technical performance of spinal anesthesia and allows for the elimination of radiation exposure.
The aim of this randomized prospectic study is to determine if the US assistance for spinal administration of nusinersen is able to increase the proportion at successful 1st needle insertion of the needle. Secondary outcome measures are procedure time, patient satisfaction and prevalence of postdural puncture headache.
Patients will be randomlized to receive a US-assisted nusinersen administration or a landmark based nusinersen administration.
intervention: US-assisted nusinersen administration
last updated: February 04, 2022
Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiat...Spinal muscular atrophy (SMA) is an auto...
Dynamic Balance in Spinal and Bulbar Muscular Atrophy: Relationship Between Strength and Performance of Forward Lung...Introduction: Spinal and bulbar muscular...
Organotypic Spinal Cord Cultures: An in Vitro 3D Model to Preliminary Screen Treatments for Spinal Muscular AtrophySpinal muscular atrophy (SMA) is a sever...
CHOP – Spinal Muscular Atrophy (SMA)Why Choose CHOP for SMA Treatment?Being ...
Spinal Muscular Atrophy and TypesWhat is Spinal Muscular Atrophy?Spinal m...
The SMA France National Registry: Already Encouraging ResultsSpinal muscular atrophy is a debilitatin...
George Z. Mentis, PhDGeorge Mentis received pursued B.Sc in P...